Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Hydrazinonicotinyl-Tyr3-Octreotide Trifluoroacetate→

Hydrazinonicotinyl-Tyr3-Octreotide Trifluoroacetate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
257943-19-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Somatostatin analogue ligandprecursor component for radiolabelled neuroendocrine-tumour imaging
Mechanism of action
A hydrazinonicotinyl-conjugated Tyr3-octreotide peptide that binds somatostatin receptors, particularly subtype 2, expressed by many neuroendocrine tumours. When radiolabelled with an appropriate radionuclide, the ligand enables scintigraphic or SPECT visualisation of receptor-positive lesions.
Indications / reported uses
  • Investigational or specialised use as a peptide precursor in radiolabelled somatostatin-receptor imaging of neuroendocrine tumours; the final radionuclide-labelled product, not the unlabelled trifluoroacetate salt, is the diagnostic agent.

Sources: https://pubmed.ncbi.nlm.nih.gov/?term=HYNIC-TOC+somatostatin+receptor+imaging · https://www.ncbi.nlm.nih.gov/mesh/?term=hydrazinonicotinyl+octreotide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Hydrazinonicotinyl-Tyr3-Octreotide Trifluoroacetate Environmental Risk Assessment (ERA) (the Hydrazinonicotinyl-Tyr3-Octreotide Trifluoroacetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.